Options or Shares?

Date: June 1, 2015 Posted by: todorbb In: Uncategorized

AstraZeneca will probably not reach revenues of 45 billion. Dollars by 2023 because of a problem with an experimental drug to treat psoriasis, which was considered a major source of revenue. Partner in the project company, Amgen, announced late Friday that terminated its cooperation with AstraZeneca on the development of drug brodalumab, as observed suicidal thoughts in patients taking the drug. AstraZeneca’s shares fell 1.5 percent so far for the day yesterday after the stock markets in the UK were closed.

Comments are currently closed.